Effect of a High Protein, Low Glycemic Index Dietary Intervention on Metabolic Dysfunction Associated Fatty Liver Disease: A Randomized Controlled Trial (IF=5.0)









 中文 EN

ACADEMIC HISKY

MAFLD Assessment of liver health Viral hepatitis Liver Cancer and Cirrhosis Evaluate the efficacy of medication Others

Effect of a High Protein, Low Glycemic Index Dietary Intervention on Metabolic Dysfunction Associated Fatty Liver Disease: A Randomized Controlled Trial (IF=5.0)

Sun P, Huang L, et al. Front Nutr. 2022 Apr 27;9:863834.

Objective

•To evaluate whether a high protein and low glycemic index (HPLG) dietary intervention would result in improvement of controlled attenuation parameter (CAP) and related metabolic markers in MAFLD.

Methods

•A 12-week controlled, parallel-group, randomized intervention trial was performed.
•A number of 63 participants with MAFLD were enrolled and randomized between the HPLG dietary group and the balanced diet control group.
•Both diets had the same hypocaloric level and were prescribed ad libitum within food limit lists. The primary outcome was CAP.

Figures & Tables

Results

•In this trial, protein and carbohydrate intakes were significantly higher and lower, respectively, in the HPLG group compared to controls (p < 0.001).
•At week 12, CAP was significantly reduced in both groups (p < 0.001). However, a significantly greater reduction in liver fat was observed in the HPLG group compared to the control group (p = 0.011), with mean relative reductions of 30.90 dB/m (95% CI, 21.53 to 40.26, p < 0.001) and 15.43 dB/m (95% CI, 7.57 to 23.30, p < 0.001), respectively.

Conclusion

•An HPLG diet led to a significant CAP remission, bodyweight or fat reduction, and improvement of metabolic markers in patients with MAFLD.

If you need more academic materials, please contact us.